Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication overuse headache: Findings from cerebrospinal fluid

Cephalalgia

Volumn 28, Issue 7, 2008, Pages 681-682

  Holland, P R ^a   Bartsch, T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; OREXIN A;

ADDICTION; BRAIN REGION; CEREBROSPINAL FLUID; DISEASE COURSE; EDITORIAL; FIBROMYALGIA; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MIGRAINE; NERVE CELL PLASTICITY; NOCICEPTION; PAIN; STRESS;

CHRONIC DISEASE; CORTICOTROPIN-RELEASING HORMONE; HEADACHE DISORDERS; HEADACHE DISORDERS, SECONDARY; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIGRAINE DISORDERS; MOTIVATION; NEUROPEPTIDES;

EID: 44849111881     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01585.x     Document Type: Editorial

References (14)

1. Rainero I, Ferrero M, Rubino E, Valfre W, Pellegrino M, Arvat E et al. Endocrine function is altered in chronic migraine patients with medication-overuse. Headache 2006 46 : 597 603.
2. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999 57 : 1 164.
3. Pinessi L, Binello E, De Martino P, Gallone S, Gentile S, Rainero I et al. The 1246G→A polymorphism of the HCRTR2 gene is not associated with migraine. Cephalalgia 2007 27 : 945 9.
4. Rainero I, Gallone S, Valfre W, Ferrero M, Angilella G, Rivoiro C et al. A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology 2004 63 : 1286 8.
5. Schurks M, Kurth T, Geissler I, Tessmann G, Diener HC, Rosskopf D. The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia 2007 27 : 363 7.
6. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004 109 : 367 78.
7. Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005 315 : 1380 5.
8. Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 2006 24 : 2825 33.
9. McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006 31 : 2776 82.
10. Leistad RB, Sand T, Westgaard RH, Nilsen KB, Stovner LJ. Stress-induced pain and muscle activity in patients with migraine and tension-type headache. Cephalalgia 2006 26 : 64 73.
11. de Tommaso M, Valeriani M, Guido M, Libro G, Specchio LM, Tonali P, Puca F. Abnormal brain processing of cutaneous pain in patients with chronic migraine. Pain 2003 101 : 25 32.
12. Fadel J, Deutch AY. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 2002 111 : 379 87.
13. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998 18 : 9996 10015.
14. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 2003 23 : 3106 11.